The name Cross-AI reflects cross-scale artificial intelligence—connecting human-level measurements from Psilmi with cellular-level activity in BrainZell’s neural organoid models. The research begins with BrainZell’s high-throughput organoid arrays, used to explore biological targets and test compounds. The companies’ AI teams will work together on linking laboratory response patterns with Psilmi measurements, including signals unfolding on different time scales. The aim is to investigate how these complementary measurements can inform understanding of drug responses across cellular models and people.
A selected subset of participants could provide matched human and organoid data. Psilmi’s underlying dataset comes from a research project at Uppsala University, and Stardots accesses it through collaboration with the university. Any use in the programme, including matched data, remains subject to consent, ethics, data-protection and donor-governance review.
While the collaboration builds on existing technologies, the combined human–organoid approach is still in the early stages of research. Any predictive or clinical applications would require further validation and, where applicable, regulatory review.
“Psilmi brings pupil responses, eye movements and cognitive performance together in one research platform. We are pleased to work with BrainZell to connect those human measurements with complementary cellular models. It is an opportunity for our teams to explore drug response from different scientific perspectives, with a shared interest in questions that matter to pharmaceutical research,” says Daniel Petrini, CEO, Stardots.
“This collaboration brings us closer to one of the greatest goals of drug development: predicting patient outcomes from preclinical models. By linking BrainZell’s human brain organoids and AI with Psilmi’s objective, real-world patient data, we can identify which biological responses truly translate into therapeutic benefit. Together, we can open a new horizon for faster, more precise, and more successful CNS drug development. We look forward to working with the Stardots team to investigate these links and what they could mean for pharmaceutical research,” says Petra Szeszula, CEO, BrainZell.
Link for more information: https://stardots.se/cross-ai-connecting-human-measurements-with-neural-organoid-research/
About Stardots
Stardots develops Psilmi, a research platform that combines synchronized pupil, eye-movement, and cognitive measures to study human function and treatment-related change.
About BrainZell
BrainZell develops patient-derived neural organoid models and assays for investigating neural biology and drug responses.
Media contacts
Stardots: Daniel Petrini, CEO, daniel.petrini@stardots.se, +46 70 782 70 01
BrainZell: Petra Szeszula, CEO, petra@brainzell.com, +46 70 926 18 34